Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/307% below fair value
$165.31−2.09 (-1.25%)
Close on Nov 16, 2026Market cap $16.80BP/E 24.2Yield –
Neurocrine Biosciences total assets
Total assets on the balance sheet at the end of each period.
Neurocrine Biosciences's total assets was $5.36B at Jun 30, 2026. For fiscal 2025 it was $4.63B, up 24.5% from the year before. Over ten years it grew 25.6% a year on average. The highest annual figure on record is $4.63B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.63B | +24.5% |
| FY2024 | Dec 31, 2024 | $3.72B | +14.4% |
| FY2023 | Dec 31, 2023 | $3.25B | +37.3% |
| FY2022 | Dec 31, 2022 | $2.37B | +14.3% |
| FY2021 | Dec 31, 2021 | $2.07B | +19.5% |
| FY2020 | Dec 31, 2020 | $1.73B | +32.8% |
| FY2019 | Dec 31, 2019 | $1.31B | +31.5% |
| FY2018 | Dec 31, 2018 | $993.15M | +21.5% |
| FY2017 | Dec 31, 2017 | $817.59M | +123.9% |
| FY2016 | Dec 31, 2016 | $365.09M | -23.1% |
| FY2015 | Dec 31, 2015 | $474.79M | +95.4% |
| FY2014 | Dec 31, 2014 | $243.03M | +57.1% |
| FY2013 | Dec 31, 2013 | $154.68M | -21.1% |
| FY2012 | Dec 31, 2012 | $195.98M | +41.6% |
| FY2011 | Dec 31, 2011 | $138.37M | -4.2% |
| FY2010 | Dec 31, 2010 | $144.42M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.36B | +37.8% |
| Q1 FY2026 | Mar 31, 2026 | $4.91B | +33.0% |
| Q4 FY2025 | Dec 31, 2025 | $4.63B | +24.5% |
| Q3 FY2025 | Sep 30, 2025 | $4.27B | +20.7% |
| Q2 FY2025 | Jun 30, 2025 | $3.89B | +17.7% |
| Q1 FY2025 | Mar 31, 2025 | $3.69B | +6.2% |
| Q4 FY2024 | Dec 31, 2024 | $3.72B | +14.4% |
| Q3 FY2024 | Sep 30, 2024 | $3.54B | +24.1% |
| Q2 FY2024 | Jun 30, 2024 | $3.31B | +26.5% |
| Q1 FY2024 | Mar 31, 2024 | $3.47B | +47.1% |
| Q4 FY2023 | Dec 31, 2023 | $3.25B | +37.3% |
| Q3 FY2023 | Sep 30, 2023 | $2.85B | +32.9% |
| Q2 FY2023 | Jun 30, 2023 | $2.61B | +30.3% |
| Q1 FY2023 | Mar 31, 2023 | $2.36B | +10.0% |
| Q4 FY2022 | Dec 31, 2022 | $2.37B | +14.3% |
| Q3 FY2022 | Sep 30, 2022 | $2.14B | +6.3% |
| Q2 FY2022 | Jun 30, 2022 | $2.01B | +2.5% |
| Q1 FY2022 | Mar 31, 2022 | $2.14B | +16.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.07B | +19.5% |
| Q3 FY2021 | Sep 30, 2021 | $2.02B | +34.3% |
| Q2 FY2021 | Jun 30, 2021 | $1.96B | +29.1% |
| Q1 FY2021 | Mar 31, 2021 | $1.85B | +35.6% |
| Q4 FY2020 | Dec 31, 2020 | $1.73B | +32.8% |
| Q3 FY2020 | Sep 30, 2020 | $1.50B | +27.3% |
| Q2 FY2020 | Jun 30, 2020 | $1.52B | +42.1% |
| Q1 FY2020 | Mar 31, 2020 | $1.36B | +42.2% |
| Q4 FY2019 | Dec 31, 2019 | $1.31B | +31.5% |
| Q3 FY2019 | Sep 30, 2019 | $1.18B | +26.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.07B | +26.8% |
| Q1 FY2019 | Mar 31, 2019 | $957.72M | +18.8% |
| Q4 FY2018 | Dec 31, 2018 | $993.15M | +21.5% |
| Q3 FY2018 | Sep 30, 2018 | $933.75M | +20.9% |
| Q2 FY2018 | Jun 30, 2018 | $841.32M | +11.6% |
| Q1 FY2018 | Mar 31, 2018 | $806.36M | +178.7% |
| Q4 FY2017 | Dec 31, 2017 | $817.59M | +123.9% |
| Q3 FY2017 | Sep 30, 2017 | $772.50M | +93.5% |
| Q2 FY2017 | Jun 30, 2017 | $754.09M | – |
| Q1 FY2017 | Mar 31, 2017 | $289.36M | – |
| Q4 FY2016 | Dec 31, 2016 | $365.09M | – |
| Q3 FY2016 | Sep 30, 2016 | $399.16M | – |
See a number that looks wrong?